spironolactone has been researched along with Vascular Calcification in 11 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Vascular Calcification: Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These observations support a putative benefit of spironolactone treatment in CKD-associated vascular calcification." | 9.41 | Protective effects of spironolactone on vascular calcification in chronic kidney disease. ( Alesutan, I; Auer, T; Buehling, SS; Degenhart, G; Feger, M; Grebe, S; Hammer, F; Hauser, T; Krane, V; Lang, F; Malzahn, U; Masyout, J; Pasch, A; Tuffaha, R; Voelkl, J; Wanner, C, 2021) |
| "Vascular calcification is frequently found already in early stages of chronic kidney disease (CKD) patients and is associated with high cardiovascular risk." | 6.50 | Impact of aldosterone on osteoinductive signaling and vascular calcification. ( Alesutan, I; Lang, F; Ritz, E; Voelkl, J, 2014) |
| "These observations support a putative benefit of spironolactone treatment in CKD-associated vascular calcification." | 5.41 | Protective effects of spironolactone on vascular calcification in chronic kidney disease. ( Alesutan, I; Auer, T; Buehling, SS; Degenhart, G; Feger, M; Grebe, S; Hammer, F; Hauser, T; Krane, V; Lang, F; Malzahn, U; Masyout, J; Pasch, A; Tuffaha, R; Voelkl, J; Wanner, C, 2021) |
| "Aldosterone (Aldo) is an important active hormone in the renin-angiotensin-aldosterone system and plays a vital role in the development of hypertension, heart failure and other cardiovascular diseases." | 5.38 | Endogenous aldosterone is involved in vascular calcification in rat. ( Cai, Y; Jia, LX; Qi, YF; Tang, CS; Wang, X; Wu, SY; Xiao, CS; Yu, YR, 2012) |
| "Vascular calcification is frequently found already in early stages of chronic kidney disease (CKD) patients and is associated with high cardiovascular risk." | 2.50 | Impact of aldosterone on osteoinductive signaling and vascular calcification. ( Alesutan, I; Lang, F; Ritz, E; Voelkl, J, 2014) |
| "Spironolactone (SPL) has been proven to improve cardiovascular outcomes in clinical trials and its protective effect on VC has been reported recently; however, the underlying mechanisms are not completely understood and require further investigation." | 1.51 | Spironolactone dose‑dependently alleviates the calcification of aortic rings cultured in hyperphosphatemic medium with or without hyperglycemia by suppressing phenotypic transition of VSMCs through downregulation of Pit‑1. ( Chen, W; Luo, D; Peng, D; Quan, Z; Wang, P, 2019) |
| "Vascular calcification is driven by aldosterone-sensitive osteogenic transformation of vascular smooth muscle cells (VSMCs)." | 1.46 | Involvement Of Vascular Aldosterone Synthase In Phosphate-Induced Osteogenic Transformation Of Vascular Smooth Muscle Cells. ( Alesutan, I; Borst, O; Castor, T; Feger, M; Gawaz, M; Kratschmar, DV; Kuro-O, M; Lang, F; Leibrock, C; Mia, S; Odermatt, A; Pieske, B; Pilz, S; Sacherer, M; Tomaschitz, A; Viereck, R; Voelkl, J; Wagner, CA, 2017) |
| "Aldosterone (Aldo) is an important active hormone in the renin-angiotensin-aldosterone system and plays a vital role in the development of hypertension, heart failure and other cardiovascular diseases." | 1.38 | Endogenous aldosterone is involved in vascular calcification in rat. ( Cai, Y; Jia, LX; Qi, YF; Tang, CS; Wang, X; Wu, SY; Xiao, CS; Yu, YR, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Hammer, F | 1 |
| Buehling, SS | 1 |
| Masyout, J | 1 |
| Malzahn, U | 1 |
| Hauser, T | 1 |
| Auer, T | 1 |
| Grebe, S | 1 |
| Feger, M | 3 |
| Tuffaha, R | 1 |
| Degenhart, G | 1 |
| Lang, F | 4 |
| Pasch, A | 1 |
| Alesutan, I | 4 |
| Wanner, C | 1 |
| Krane, V | 1 |
| Voelkl, J | 4 |
| Zhang, X | 1 |
| Zhou, X | 1 |
| Huang, Z | 1 |
| Fan, X | 1 |
| Tan, X | 1 |
| Lu, C | 1 |
| Yang, J | 1 |
| Pluquet, M | 1 |
| Kamel, S | 1 |
| Choukroun, G | 1 |
| Liabeuf, S | 1 |
| Laville, SM | 1 |
| Gueiros, APS | 1 |
| Gueiros, JEB | 1 |
| Nóbrega, KT | 1 |
| Calado, EB | 1 |
| Matta, MCD | 1 |
| Torres, LC | 1 |
| Souza, ASR | 1 |
| Casarini, DE | 1 |
| Carvalho, AB | 1 |
| Kratschmar, DV | 1 |
| Castor, T | 1 |
| Mia, S | 2 |
| Sacherer, M | 1 |
| Viereck, R | 1 |
| Borst, O | 1 |
| Leibrock, C | 1 |
| Gawaz, M | 1 |
| Kuro-O, M | 2 |
| Pilz, S | 1 |
| Tomaschitz, A | 1 |
| Odermatt, A | 1 |
| Pieske, B | 1 |
| Wagner, CA | 1 |
| Wang, P | 1 |
| Quan, Z | 1 |
| Luo, D | 1 |
| Chen, W | 1 |
| Peng, D | 1 |
| Ritz, E | 1 |
| Tatsumoto, N | 1 |
| Yamada, S | 1 |
| Tokumoto, M | 1 |
| Eriguchi, M | 1 |
| Noguchi, H | 1 |
| Torisu, K | 1 |
| Tsuruya, K | 1 |
| Kitazono, T | 1 |
| Zhu, D | 1 |
| Rashdan, NA | 1 |
| Chapman, KE | 1 |
| Hadoke, PW | 1 |
| MacRae, VE | 1 |
| Wu, SY | 1 |
| Yu, YR | 1 |
| Cai, Y | 1 |
| Jia, LX | 1 |
| Wang, X | 1 |
| Xiao, CS | 1 |
| Tang, CS | 1 |
| Qi, YF | 1 |
| Leibrock, CB | 1 |
| Quintanilla-Martinez, L | 1 |
| Kuhn, V | 1 |
| Ahmed, MS | 1 |
| Rosenblatt, KP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients[NCT03314493] | Phase 3 | 33 participants (Actual) | Interventional | 2014-11-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for spironolactone and Vascular Calcification
| Article | Year |
|---|---|
Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review.
Topics: Biomarkers; Calcium Phosphates; Citrates; Dialysis Solutions; Humans; Magnesium; Renal Insufficiency | 2022 |
Impact of aldosterone on osteoinductive signaling and vascular calcification.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Humans; Hyperphosphatemia; Mice; Mineralocorticoid Re | 2014 |
2 trials available for spironolactone and Vascular Calcification
| Article | Year |
|---|---|
Protective effects of spironolactone on vascular calcification in chronic kidney disease.
Topics: Aldosterone; Alkaline Phosphatase; Animals; Aorta; Biomarkers; Cholecalciferol; Core Binding Factor | 2021 |
Effect of spironolactone on the progression of coronary calcification in peritoneal dialysis patients: a pilot study.
Topics: Aged; Calcium; Cholesterol, LDL; Disease Progression; Female; Follow-Up Studies; Humans; Lost to Fol | 2019 |
7 other studies available for spironolactone and Vascular Calcification
| Article | Year |
|---|---|
Aldosterone is a possible new stimulating factor for promoting vascular calcification.
Topics: Aldosterone; Animals; Aorta; Rats; Renin-Angiotensin System; Spironolactone; Vascular Calcification | 2021 |
Involvement Of Vascular Aldosterone Synthase In Phosphate-Induced Osteogenic Transformation Of Vascular Smooth Muscle Cells.
Topics: Adrenalectomy; Aldosterone; Aorta; Coronary Vessels; Cytochrome P-450 CYP11B2; Gene Expression Regul | 2017 |
Spironolactone dose‑dependently alleviates the calcification of aortic rings cultured in hyperphosphatemic medium with or without hyperglycemia by suppressing phenotypic transition of VSMCs through downregulation of Pit‑1.
Topics: Animals; Dose-Response Relationship, Drug; Gene Expression Regulation; Hyperphosphatemia; Immunophen | 2019 |
Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
Topics: Adenine; Animals; Aorta, Abdominal; Aortic Diseases; Apoptosis; Biomarkers; Disease Models, Animal; | 2015 |
A novel role for the mineralocorticoid receptor in glucocorticoid driven vascular calcification.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apoptosis; Corticosterone; Disease Models, Ani | 2016 |
Endogenous aldosterone is involved in vascular calcification in rat.
Topics: Aldosterone; Alkaline Phosphatase; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals | 2012 |
Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice.
Topics: Aldosterone; Animals; Cell Differentiation; Cells, Cultured; Fibroblast Growth Factor-23; Fibroblast | 2013 |